3-(3-methoxyphenyl)propanoyl chloride | 40478-49-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-(3-methoxyphenyl)propanoyl chloride
• CAS: 40478-49-7
• 化学式: C₁₀H₁₁ClO₂
• 分子量: 198.649
• InChiKey: YIBRVNQKMYAOIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(3-methoxyphenyl)propanoyl chloride 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以2.53 g的产率得到3-(3-甲氧基苯基)-1-丙醇
  参考文献：
  名称：

  Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: Highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site

  摘要：

  On the basis of X-ray co-crystal structures of matrix metalloproteinase-13 (MMP-13) in complex with its inhibitors, our structure-based drug design (SBDD) strategy was directed to achieving high affinity through optimal protein-ligand interaction with the unique S1 '' hydrophobic specificity pocket. This report details the optimization of lead compound 44 to highly potent and selective MMP-13 inhibitors based on fused pyrimidine scaffolds represented by the thienopyrimidin-4-one 26c. Furthermore, we have examined the release of collagen fragments from bovine nasal cartilage in response to a combination of IL-1 and oncostatin M. (C) 2014 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2014.07.025
• 作为产物：
  描述：

  3-Methoxycinnamic acid 在 铂 氯化亚砜 、 氢气 作用下， 以 乙醇 、 苯 为溶剂， 生成 3-(3-methoxyphenyl)propanoyl chloride
  参考文献：
  名称：

  Charlton, James Leslie.; Lai, Hoi Kiong.; Lypka, Gerald Nicholas, Canadian Journal of Chemistry, 1980, vol. 58, p. 458 - 462

  摘要：

  DOI：

文献信息

• Vinylogous carbinolamine tumor inhibitors. 23. Synthesis and antileukemic activity of bis[[(carbamoyl)oxy]methyl]-substituted pyrrolo[2,1-a]isoquinolines, pyrrolo[1,2-a]quinolines, pyrrolo[2,1-a]isobenzazepines, and pyrrolo[1,2-a]benzazepines
  作者：Wayne K. Anderson、Arvela R. Heider、Natarajan Raju、Jeffery A. Yucht

  DOI：10.1021/jm00119a008

  日期：1988.11

  compound or with a mesoionic oxazolone intermediate. All of the bis(carbamates) were active in vivo against P388 lymphocytic leukemia with 5,6-dihydro-8-methoxy-1,2- bis(hydroxymethyl)pyrrolo[2,1-a]isoquinoline bis[N-(2-propyl)carbamate] (3c) showing the highest level of activity.

  通过与合适的Resissert化合物的三氟甲磺酸盐或与中离子的恶唑酮中间体进行1,3-偶极环加成反应，合成了一系列双[[（氨基甲酰基）氧基]甲基]-取代的吡咯稠合的三环杂环。所有的双（氨基甲酸酯）在体内均具有5,6-二氢-8-甲氧基-1,2-双（羟甲基）吡咯并[2,1-a]异喹啉双[N-（2-）对P388淋巴细胞性白血病的活性。丙基]氨基甲酸酯]（3c）表现出最高的活性水平。
• Development of novel 2,4-bispyridyl thiophene–based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives
  作者：Sarah S. Darwish、Mohammad Abdel-Halim、Mohamed Salah、Ashraf H. Abadi、Walter Becker、Matthias Engel

  DOI：10.1016/j.ejmech.2018.07.050

  日期：2018.9

  effects especially over long treatment periods. Herein, we describe the design and synthesis of a series of amide functionalized 2,4-bispyridyl thiophene compounds, of which the 4-fluorobenzyl amide derivative (31b) displayed the highest potency against Dyrk1A and remarkable selectivity over closely related kinases (IC50: Dyrk1A = 14.3 nM; Dyrk1B = 383 nM, Clk1 > 2 μM). This degree of selectivity over

  蛋白激酶Dyrk1A调节与阿尔茨海默氏病（AD）的发生或发展相关的多个过程，例如通过tau蛋白，淀粉样前体蛋白（APP）的磷酸化以及与tau pre-mRNA的选择性剪接相关的蛋白。因此，Dyrk1A已被提议作为治疗AD的潜在靶标。但是，对同一个蛋白激酶家族的其他紧密相关的激酶（例如Dyrk1B和Dyrk2）或其他家族的激酶（例如Clk1）的共抑制作用限制了Dyrk1A抑制剂的使用，因为这可能会导致无法预料的副作用，尤其是在长期治疗中时期。在这里，我们描述了一系列酰胺官能化的2,4-双吡啶基噻吩化合物的设计和合成，其中4-氟苄基酰胺衍生物（31b）显示出对Dyrk1A的最高效力，并且比紧密相关的激酶具有显着的选择性（IC 50：Dyrk1A = 14.3 nM; Dyrk1B = 383 nM，Clk1> 2μM）。迄今为止，很少能达到对频繁击中目标的选择性。此外，31b在完整细胞中以高效率抑制了Dyrk1A（IC
• Monoamine re-uptake inhibiting 1-[2-[(phenoxyphenyl)methoxy]ethyl]- piperazines as potential antidepressants
  作者：J. Wieringa、A. van den Meerendonk、J. Steenvoorden、G. Heeres、F. van Bakel、T. Roeters、R. van der Hulst、A. Den Blanken、D. Leysen、R. Plate、Th. de Boer、H. Rijk

  DOI：10.1002/recl.19931120212

  日期：——

  A series of 1-[2-[(2-phenoxyphenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines 17–50 (Figure 1) were prepared and tested as inhibitors of biogenic amine re-uptake. In our search for antidepressants, the relationship between their in vitro and in vivo activity as dopamine-reuptake inhibitors is described quantitatively by using Retention Index values determined by reversed-phase liquid chromatography

  一系列的1- [2 - [（2-苯氧基苯基）甲氧基]乙基] -4-（3-苯基丙基）哌嗪17-50（图1）的制备和作为生物胺再摄取抑制剂的测试。在我们的抗抑郁药的搜索，它们之间的关系的体外和体内活性的多巴胺再摄取抑制剂是通过使用反相液相色谱法测定保留指数值定量描述。
• ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES
  申请人：Herman Jean

  公开号：US20140088088A1

  公开（公告）日：2014-03-27

  The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, Formulas (I), (II), (III) and (IV) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11 , and R 12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent proliferative disorders and their use to manufacture a medicine to treat or prevent proliferative disorders, particularly cancer such as leukemia. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent proliferative disorders. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of proliferative disorders and pathologic conditions such as, but not limited to, cancer such as leukemia.

  本发明涉及式I、II、III或IV的化合物，和/或其药用可接受的加合物盐和/或其立体异构体和/或其溶剂化合物，式(I)、(II)、(III)和(IV)中R1、R2、R3、R4、R5、R6、R7、R8、R9、R11和R12如权利要求书中所定义或在发明说明书中详细描述的那样，以及使用所述化合物来治疗或预防增殖性疾病以及用于制造治疗或预防增殖性疾病的药物，特别是像白血病这样的癌症。本发明还涉及所述化合物的药物组合物以及使用所述药物组合物来治疗或预防增殖性疾病。本发明还涉及将所述化合物用作生物活性成分，更具体地用作治疗增殖性疾病和病理状况的药物，例如癌症如白血病等。
• α,α-Alkylation-Halogenation and Dihalogenation of Sulfoxonium Ylides. A Direct Preparation of Geminal Difunctionalized Ketones
  作者：Rafael D. C. Gallo、Anees Ahmad、Gustavo Metzker、Antonio C. B. Burtoloso

  DOI：10.1002/chem.201704609

  日期：2017.12.1

  A one‐pot alkylation–halogenation of ketosulfoxonium ylides in the presence of alkyl halides is described. The method furnishes several gem‐difunctionalized haloketones (an alkyl and F, Cl, Br, or I) in good yields. Replacing alkyl halides with a mixture of electrophilic halogen species and various halide anions led to gem‐dihalogenated ketones containing a combination of the same or two different

  描述了在存在烷基卤化物的情况下一酮醚化ox酮的一锅烷基化-卤化反应。该方法以良好的收率提供了几种宝石双官能化的卤代酮（烷基和F，Cl，Br或I）。用亲电子卤素物质和各种卤化物阴离子的混合物代替烷基卤化物，会导致宝石二卤代酮含有相同或两种不同卤素的组合。动力学同位素效应以及反应动力学实验使人们洞悉了这些反应的机理。